Croatia to fund RSV immunization for infants

The Croatian Health Insurance Fund (HZZO) will fund immunization for infants against the respiratory syncytial virus (RSV) this season. Following recommendations from the Croatian Pediatric Society, the Ministry of Health has approved the provision of long-acting monoclonal antibodies to protect children during their first RSV season.

RSV is a common cause of respiratory infections that can lead to severe conditions in infants, such as bronchiolitis, pneumonia, and respiratory failure, potentially requiring intensive care. The new measure aims to protect all children entering their first RSV season, regardless of whether they have specific risk factors, though protection for children over one year old will remain focused on high-risk groups.

The immunization is passive and involves a single dose of long-acting monoclonal antibodies, such as nirsevimab or clesrovimab, which provide protection throughout the RSV season, typically spanning from October to March. Children born during the season are expected to receive the dose in the maternity ward before discharge, while those born earlier in the year will receive it through their chosen pediatrician.